(MENAFN- GlobeNewsWire - Nasdaq) The nasal polyps market presents opportunities with multiple pipeline drugs in various development stages, targeting novel treatment approaches. Focused efforts by key players like AstraZeneca highlight potential growth in addressing chronic rhinosinusitis with nasal polyps using advanced therapies, such as Tezepelumab.

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Nasal Polyps - Pipeline Insight, 2025" has been added to ResearchAndMarkets's offering.

The Nasal Polyps - Pipeline Insight, 2025 report offers detailed insights into the evolving landscape of Nasal Polyps treatment, highlighting ongoing research and development activities. The report covers a spectrum of 4+ companies and their diverse pipeline drugs in various stages, from clinical to nonclinical. It includes assessments based on product type, stage of development, administration route, and molecule type, also shedding light on inactive pipeline products.

Nasal polyps, noncancerous growths in the nasal passage lining, often occur in patients with chronic rhinosinusitis. They are also linked with conditions like aspirin-exacerbated respiratory disease and cystic fibrosis. These polyps, stemming from unchecked allergies, significantly impair patients' quality of life, presenting symptoms ranging from nasal obstruction and congestion to anosmia and rhinorrhea. Their development is influenced by anatomical and functional changes as one ages, alongside conditions like impaired mucociliary clearance and hereditary factors.

Treatment typically entails addressing the polyps before implementing therapies to control the underlying allergies. Diagnosis primarily involves rhinoscopy or endoscopy, with imaging being crucial if complications like fungal infections or tumors are suspected. Corticosteroids remain the cornerstone for managing polyp size, with nasal sprays like budesonide and fluticasone propionate offering relief. In severe cases, oral corticosteroids are administered in tapered doses. While antibiotics are prescribed for acute infections, their role in chronic cases remains debated, though ongoing trials explore their efficacy.

The report emphasizes the current scenario and prospective growth within the Nasal Polyps treatment domain, providing a thorough analysis of the disease, treatment guidelines, and pipeline landscape. It highlights the commercial and clinical assessments of pipeline products, detailing drugs' mechanisms of action, clinical studies, approvals, and development activities, including collaborations, licensing, and mergers.

Key developments feature companies and researchers striving to navigate challenges and seize opportunities in Nasal Polyps R&D, focusing on innovative approaches to treatment. The emerging drugs section explores various clinical phases, detailing trials, pharmacological actions, and recent collaborations.

A stand-out drug is Tezepelumab, developed by AstraZeneca and Amgen, targeting TSLP, a critical cytokine in inflammation. Currently in Phase III for treating Chronic Rhinosinusitis with Nasal Polyps, it promises to manage airway inflammation effectively.

The report further classifies drugs by administration route and molecule type, offering insights into major players and development stages, from preclinical stages to discontinued projects. It covers about 4+ products across late, mid, and early stages, and provides a comprehensive overview of therapeutic assessments, unmet needs, and potential impacts of these drugs.

Key players like AstraZeneca and KeyMed Biosciences are pivotal in advancing treatments, with products such as CM-310 and Tezepelumab leading the way.

Key Topics Covered:

Introduction

Executive Summary

Nasal Polyps: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Nasal Polyps - Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Tezepelumab: AstraZeneca

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Early Stage Products (Phase I)

• Comparative Analysis

Preclinical and Discovery Stage Products

• Comparative Analysis

Inactive Products

• Comparative Analysis

Nasal Polyps Key Companies

Nasal Polyps Key Products

Nasal Polyps - Unmet Needs

Nasal Polyps - Market Drivers and Barriers

Nasal Polyps - Future Perspectives and Conclusion

Nasal Polyps Analyst Views

Appendix

Companies Featured

• AstraZeneca
• KeyMed Biosciences

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN22102025004107003653ID1110231403